Author

A. Nist

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:cell type annotation· 4 Research Focus:drug response / drug discovery· 4 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

T. Stiewe· 7 shared M. Mernberger· 4 shared J. Cinatl· 2 shared M. Michaelis· 2 shared M. N. Wass· 2 shared M. Wanzel· 2 shared A. Borowek· 1 shared A. Burchert· 1 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersCancer Biology

T. Stiewe

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

H. E. Grimsley, M. Antczak, I. G. Reddin, K.-M. McLaughlin, A. Nist, M. Mernberger, T. Stiewe, T. R. Fenton, D. Speidel, C. Harper-Wynne, K. Cox, J. Cinatl, M. N. Wass, M. Garrett, M. Michaelis

This study identifies drug-resistant sublines of TNBC cell lines and finds that resistance mechanisms are unique and unpredictable, suggesting new potential drug targets.

bioRxiv · Jan 20, 2024 · PreprintCancer Biology

Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis

J. Funk, M. Klimovich, E. Pavlakis, M. Neumann, D. Drangenstein, M. Noeparast, P. Hunold, A. Borowek, D.-I. Balourdas, K. Kochan, N. Merle, I. Bullwinkel, M. Wanzel, S. Elmshauser, A. Nist, , T. Stiewe

This study uses CRISPR mutagenesis to analyze the functional impact of TP53 mutations across 9,225 variants, revealing their effects on tumor cell fitness and metastasis.

bioRxiv · Mar 10, 2023Cancer Biology

Haptoglobin buffers lipopolysaccharides to safeguard against aberrant NFκB activation

L. Zein, J. Grossmann, H. Swoboda, C. Borgel, B. Wilke, S. Awe, A. Nist, T. Stiewe, O. Stehling, S.-A. Freibert, T. Adhikary, H.-R. Chung

This study shows haptoglobin binds and buffers lipopolysaccharides to delay NFκB activation in macrophages, suggesting its role in preventing aberrant inflammation.

bioRxiv · Nov 22, 2022 · PreprintImmunology

Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells

S. Fischer, V. T. Trinh, C. Simon, L. M. Weber, I. Forne, A. Nist, G. Bange, F. Abendroth, T. Stiewe, W. Steinchen, R. Liefke, O. Vazquez

The paper develops a peptide inhibitor targeting the Elongin BC dimer, showing reduced cancer cell viability and increased apoptosis by blocking its interaction partners.

bioRxiv · Nov 4, 2022Cancer Biology

IRF4 deficiency vulnerates B cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity

D. Das Gupta, C. Paul, N. Samel, M. Bieringer, D. Staudenraus, F. Marini, H. Raifer, L. Menke, L. Hansal, B. Camara, E. Roth, P. Daum, M. Wanzel, M. Mernberger, A. Nist, , M. Lohoff

This study shows IRF4 deficiency leads to B cell leukemia via Jak3 mutations that increase IL-7 sensitivity, and JAK inhibition improves survival in a mouse model.

bioRxiv · Feb 16, 2022 · PreprintCancer Biology

Single cell RNA-seq uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19

M. Aznaourova, N. Schmerer, H. Janga, Z. Zhang, K. Pauck, J. Hoppe, S. M. Volkers, D. Wendisch, P. Georg, M. Guendisch, E. Mack, C. Skevaki, C. Keller, C. Bauer, W. Bertrams, , L. N. Schulte

The paper identifies PIRAT, a lncRNA regulating monocyte immunity in COVID-19 via PU.1 feedback, and shows its role in alarmin production.

bioRxiv · Nov 5, 2021 · PreprintImmunology

Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

M. Michaelis, M. N. Wass, I. Reddin, Y. Voges, F. Rothweiler, S. Hehlgans, J. Cinatl, M. Mernberger, A. Nist, T. Stiewe, F. Roedel, J. Cinatl

The paper investigates drug-induced heterogeneity in cancer cell lines and identifies biomarkers for acquired resistance to YM155.

bioRxiv · Feb 13, 2020Pharmacology & Toxicology